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Recent developments in cancer care in France 
Competition or coordinated care? 
Patrick Castel1
 
Patrice Pinell (2002) has analysed the birth of a national policy to fight against cancer in 
France at the beginning of the 20th century and how this policy came to be articulated around 
a restricted number of hospitals specialised in cancer care. In those times, their characteristics 
were innovative, since these hospitals should manage research activities and treat patients at 
the same time while defending a multidisciplinary approach to cancer care. This meant that 
each medical speciality was to participate in the therapeutic decision process. The defence and 
promotion of radiotherapy as an emerging technique beside the dominant surgery methods 
was a major concern for the founders of these cancer centres. 
From their creation to the 1970s, these Cancer Centres were the main organisations in charge 
of cancer patients in France. In 1965, the French government entrusted them with organising 
consultations for patients in other hospitals in their regions. Until 1972, physicians appointed 
to the National Commission in charge of advising the government to define a national cancer 
policy were exclusively drawn from the Cancer Centres, as well. 
But from then on, things changed. Cancer Centres have faced increasing competition (by 
Teaching Hospitals and general healthcare organisations) and their legitimacy has been 
challenged by other healthcare actors and organisations (especially by organ specialists who 
contested their pathology-oriented and multidisciplinary approach). In this paper, I will sketch 
out two reform projects which greatly contributed to reinstate cancer centres as cornerstones 
in the French oncology sector. This movement shared two important characteristics with other 
past reforms (see P. Pinell): 
• it was a centralised, national impetus; 
• it aimed at normalising medical practices and the organisation of cancer care. 
As we will see, this reform program clearly leaned on previous achievements as well as on 
some of the CC’s organisational and cultural characteristics. But it was specific in two main 
ways: 
• it aimed at defending and promoting medical oncology as an emerging speciality inside 
and outside cancer centres whereas radiotherapy and surgery had been the dominant 
specialities until then; 
• normalisation was to be achieved through randomised clinical trials and (evidence-based) 
practice guidelines. 
I focused my paper on three dimensions of this reform, so that it may facilitate discussions 
and international comparisons during the workshop: 
• reasons why this reform was launched; 
• conditions that might have facilitated its implementation; 
• some current characteristics of the organisation of cancer care in France2. 
                                                 
1 Sciences Po, Centre de Sociologie des Organisations ; CNRS. p.castel@cso.cnrs.fr 
2 I am well aware that every topic deserves further developments and, most of all, that the logical link between 
the three should be explicated. 
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Reasons underlying normalisation 
 
At the beginning of the 1990s, a group of 5 physicians at the head of cancer centres launched 
a reform program with the goal of normalising medical practices inside and outside cancer 
centres. They argued that the National Federation of Cancer Centres, an employers’ 
association which was created in 1964 and whose board was composed of the 20 directors of 
CCs, should develop evidence-based guidelines and sponsor clinical trials. The reasons vary 
why they decided to design this reform. 
 
Common interest and similar career paths 
The CCs’ reformers shared a number of distinctive features and a personal adherence to the 
evidence-based medicine program. They belonged to what Marks (1997) would have called 
therapeutic reformers: they believed in the necessity to improve efficiency and reduce the 
heterogeneity of medical practices through the development of rational methods. 
First, their medical specialisation contrasted with those of the previous directors in the centre 
in which they were nominated. Three of them were the first medical oncologists to be 
nominated at the head of a Cancer Centre while the fourth was the first radiotherapist 
following three surgeons and a pathologist: in other words, they shared a disciplinary interest 
in the face of surgery as another, still dominant treatment technique. 
Secondly, they had been actively involved in (international) research activities, a fact which 
strongly contrasted with other directors of the National Federation’s board. In particular, the 
three medical oncologists had been appointed as research fellows in some of the most famous 
American institutions who developed new medical treatments through experimental research 
and multicentre clinical trials3. 
As concerns the guidelines project, its instigator, a paediatric oncologist, could not abide by 
the heterogeneity among treatments which were prescribed by physicians in his centre, since 
they could imply inequalities among patients. He was all the more sensitive to this issue in 
that the international community of paediatric oncologists had been involved for many years 
in the question of the harmonisation of their practices (Castel and Dalgalarrondo, 2005). 
 
Normalisation for legitimacy 
But the normalisation program was also based on more utilitarian grounds: it aimed at 
reinstating cancer centres as leaders in the French oncology sector. Indeed, from the 1980s on, 
these centres had faced increasing criticisms by regulatory bodies and other healthcare actors 
and organisations. If they were to survive, they had to prove that they were still useful. 
First, general (for-profit and non-profit) hospitals had greatly increased their participation in 
cancer care. Cancer Centres possessed only 22 percent of the French radiotherapy equipment 
by the end of the 1970s, while they had heavily based their development on this technique. 
Moreover, the emergence of chemotherapy allowed new categories of physicians, who were 
not specialised in radiotherapy or surgery, to enter the field of cancer care4. As a consequence, 
the number of new cancer patients treated in the CCs stagnated during the 1980s whereas the 
                                                 
3 Two of them, who later were to assume the leadership of national scientific projects, had been research fellows 
at the Fred Hutchinson Cancer Research in Seattle. This institution specialised in haematology and in particular 
in bone marrow transplantation which was a new technique intended to allow the prescription of higher doses of 
chemotherapy to patients. When they came back to France, they both became director of a bone marrow 
transplant service in their respective centres, founded the French association of bone marrow transplantation and 
became advisers for the Ministry of Health in this area. Later on, they spent some months in the NCI laboratories 
of Prof. Steven Rosenberg, who was a much reputed specialist of Interleukin 2. 
4 In France, oncologists are not the only physicians allowed to prescribe chemotherapy. 
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total number of cancer patients grew. Furthermore, the number of hospitals relying on CCs’ 
physicians for cancer consultations stagnated to around 150 during the 1980s. 
Secondly, some healthcare organisations promoted an alternative medical model that 
challenged the CCs’. They were organised around physicians specialised in the treatment of 
specific organs (gynaecologists, urologists, gastro-enterologists, etc.), cancer being only one 
among many other pathologies they treated, whereas Cancer Centres claimed that only 
physicians specialised in the knowledge of the pathology as a whole (oncologists) were able 
to propose the appropriate treatments. The Teaching Hospitals, created in 1958 (i.e. after the 
CCs), were particularly threatening for CCs. Having become the keystone of the French 
healthcare system, since they were perceived as offering the best and most advanced 
treatments, to train physicians and to conduct medical research for all pathologies, they began 
to claim from the 1980s on that Cancer Centres were no longer useful and argued that their 
physicians, specialised in organ treatments and at the forefront of clinical research, were thus 
more qualified to treat cancer. 
In this competitive context, several public reports raised the question of maintaining these 
atypical hospitals: they were costly and did not show any evidence of their added value. 
The normalisation program was conceived as an answer to all these challenges. 
First, it was expected that the sponsorship of (multicentre) clinical trials and the elaboration of 
guidelines by CCs would contribute to prove the pre-eminence of their physicians and of their 
pathology-oriented and multidisciplinary approach in the oncology sector. For instance, 
through the guidelines project, they came up to regulatory bodies’ expectations which tried to 
promote a quality approach in the French healthcare sector in order to curb expenditures 
(Setbon, 2000; Kerleau, 1998). Furthermore, homogeneity of practices inside CCs was 
expected to reinforce their professional legitimacy5. 
Secondly, both activities – guidelines’ elaboration and clinical research – could help to 
differentiate these centres and their physicians from other healthcare organisations. They were 
intended to make clear the “added value” of cancer centres in the French oncology sector. At 
that time, there was not any national cancer guideline in France although, given the increasing 
number of randomised controlled trials, reformers were convinced that professionals would 
welcome some help to stay well informed on current treatments. As concerns clinical 
research, objectives were twofold. On the one hand, an increasing participation of CCs’ 
physicians in clinical trials could differentiate them from “rank-and-file” practitioners who 
only treated individual patients. On the other hand, the NFCC should (and indeed would) 
become the main public sponsor of clinical trials in France and thus differentiate CCs from 
Teaching Hospitals – since the latter had not developed such a co-ordinated activity at the 
national level. 
Last but not least, the guidelines project was seen by the directors as a way to set the rules in 
the oncology sector. In particular, it was a tool to defend 1) the usefulness of radiotherapy and 
medical treatments besides surgery and 2) the medical approach and organisation of cancer 
care which CCs’ physicians have developed (Pinell, 2002). Thus, one of the first guidelines 
elaborated by the CCs was entitled “Standards, Options and Recommendations concerning 
good practices in the multidisciplinary organisation of cancer care” (Chardot, Fervers et al., 
1995). 
                                                 
5 By the end of the 1980s, the instigator of the guidelines project (recently appointed as director of his centre), 
analysed that heterogeneity of practices inside his centre was indeed an obstacle to the regional legitimacy of his 
centre. Because of this heterogeneity, physicians of other hospitals explicitly cast in doubt the quality of the 
advice that CC’s physicians offered them. 
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Favourable conditions and social skilfulness 
The reformers of Cancer Centres can be defined in Fligstein’s words as “socially skilled 
actors” (2001). On the one hand, they succeeded in making sense of the situation that 
directors and physicians of Cancer Centres were encountering and in redefining their 
collective interests and identity. On the other hand, they were pragmatic enough to use the 
resources at hand and induce co-operation among actors. 
Collective identity as a resource for change 
While pushing for drastic reform along the lines which they sketched out, the group of 
reformers argued that their program was in line with, and therefore able to protect and to 
enhance, the founding project of Cancer Centres (Pinell, 2002) of which directors and 
physicians are very proud. They underlined that the two distinctive organisational features of 
Cancer Centres (their specialisation around the pathology and their multidisciplinary 
organisation), were seriously threatened by other medical approaches. They also recalled that 
the initial missions of Cancer Centres were not only to treat patients but also to have an 
influence on general cancer care : their proposal to produce medical guidelines and to develop 
research were presented as a way to regain scientific legitimacy and leadership. 
The insistence on multi-disciplinarity, on collegiality and on a pathology-centred approach to 
cancer care was capitalising on the specific competence and skills (Selznick, 1957) of Cancer 
Centres, which was their historical identity. Indeed, this identity was used as a basis and as a 
tool of mobilisation in favour of change. And this model did in fact provide peculiar resources 
to push along other important dimensions of the reform. For instance, thanks to their 
multidisciplinary organisation, physicians in Cancer Centres had grown accustomed to 
showing their patients’ records to each other and to discuss with each other the best 
therapeutic strategy, it transpired that they were ready to understand the utility of guidelines 
as a co-ordinating mechanism. These meetings would also prove to be a resource to enrol 
patients in NFCC’s trials: since many cases were collegially discussed, medical oncologists 
had the opportunity to screen patients more easily and remind their colleagues that these 
patients could be enrolled in federal trials. 
Federal resources 
Reformers capitalised on other existing collective patterns to implement their program. Not to 
mention that the unified classification of tumours which was formalised years ago was a sine 
qua non condition to develop clinical trials and guidelines. Reformers also involved 
physicians who had been active in inter-centre scientific groups. These groups had conducted 
smaller clinical trials and had organised “open” collective reflection on some scientific topics 
since the 1970s. For instance, at the beginning of the guidelines’ project, 26 out of 28 federal 
task groups were animated by a physician who had previous responsibilities in these inter-
centre groups. These groups constituted a valuable resource for this project since physicians 
who had participated in them had learnt how to collaborate with each other and were 
interested in harmonising practices. Furthermore, their leaders had acquired a kind of 
legitimacy inside the CC’s professional community. Last but not least, the traditional close 
relationships between CCs and the National League Against Cancer certainly facilitated that 
this association of patients accepted funding these federal projects. 
 
Centralisation, informal hierarchy and “medical oncologisation” 
 
A more centralised and unified organisational field 
Traditionally, the federation was an employers’ organisation with weak prerogatives. While 
there were of course differences in the influence of individual directors, the organisational 
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model seemed more like a confederation of highly autonomous centres than like a unified 
organisation. The situation today is quite different. By the end of the 1990s, the National 
Federation has grown bigger, stronger and more influent: 1) it has gained a significant 
increase in resources (see Annex 1), 2) its legitimacy to initiate and lead collective projects 
for the 20 Cancer Centres has been acknowledged and enacted, and 3) strategic orientations of 
Cancer Centres are congruent with the federal reform. The Federation also defines the clinical 
trials which are to be developed, decides when a trial needs to be ended earlier than expected 
because of too small accrual, while also monitoring these trials – thus intervening in medical 
practices. 
Furthermore, the Federation is more influential. Cancer Centres’ strategic plans are very 
similar to each other and congruent with the reform. Each strategic plan emphasises that the 
Cancer Centre intends henceforth to be a centre for assistance and expertise for other 
healthcare organisations in their particular region rather than their competitor. And the 
development of research activities and the improvement of the quality of care through 
treatment protocols and patients’ participation are identified as priorities in every Cancer 
Centre, even in the centres which had been focused previously only on care. 
Nowadays, this trend toward centralisation continues with the creation of a national cancer 
institute in 2004. This new public agency intends to regulate the organisation of cancer care 
and research. It is the result of a longstanding initiative by NFCC’s reformers, which allied 
with some others opinion leaders who worked in Teaching Hospitals. It therefore comes as no 
surprise if this institute carries on former major projects of the NFCC and intends to 
generalise the creation of multidisciplinary staffs. Furthermore, it is now presided by the 
former director of the NFCC’s project for clinical research. This represents an adoption of 
CCs’ medical model which they have defended and promoted all along the reform. 
A regional reorganisation of cancer care 
At the regional level, CCs’ physicians play a leading role in the creation of co-operative 
networks for the elaboration and implementation of regional treatment protocols adapted to 
the characteristics and resources of the local healthcare system in order to be relevant and 
accessible for everyday practice6. Local networks for the implementation of guidelines 
became the organisational infra-structure for exchange around difficult cases and the de facto 
grading of regional cancer-care: the “normal” cases for small non-profit and for-profit 
hospitals, the difficult cases for the Cancer Centres and the Teaching Hospital(s). 55% of 
CCs’ patients are recruited outside their nearby territory, reflecting their role of support for 
the other organisations. Even when they do not treat patients, CCs’ physicians do participate 
very often in the treatment decisions. In 2000, Cancer Centres’ physicians were invited to 200 
hospitals to discuss medical cases of local patients. This shows an increase in comparison to 
the 1980s (see above). Furthermore, between 1995 and 2000, the number of medical records 
which have been seen by CCs’ physicians during these meetings has grown up from 33.000 to 
50.000. 
Evolution of physicians’ work and intra-professional legitimacy 
Decision in the medical field is becoming more and more a collective process. Not only are  
physicians expected to conform to guidelines, but they have to participate in multidisciplinary 
staffs where therapeutic decisions for their own patients are collegially discussed. Even when 
no available guideline fits with specific cases, physicians have to justify therapeutic decisions 
using scientific references (and especially the results of clinical trials). 
                                                 
6 This entails two activities. First, it means initiating and monitoring the discussion process at the regional level 
through which federal review monographs are transformed into decision algorithms and into specific 
recommendations of one among several scientifically appropriate treatments. 
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This is not a “pure” de-professionalisation process, since: 
• only physicians participate (for example, patients and economists are excluded from 
guidelines’ elaboration); 
• they can refuse to participate in clinical trials; 
• medical audits are very rare and do not lead to sanctions (so far). 
This has more to do with a “lateral control regime” (Laszega, 2000), consisting in increasing 
informal and horizontal control among peers. However, one may notice that medical 
oncologists are becoming more and more central in the organisation of cancer care in France, 
although at the same time nobody denies that surgery remains the most efficient treatment for 
most cancers. This will require further (comparative) analyses but one may argue that this is 
much due to the normalisation process. First, medical oncologists are the most involved 
specialists in clinical research. Secondly, and consequently, since specific therapeutic 
decisions and guidelines have to be grounded on the results of clinical research, medical 
oncologists are more likely to intervene in, and master, processes of collective deliberation. 
Thirdly, the development of multidisciplinary staffs allows medical oncologist to intervene 
earlier in patients’ trajectories, whereas they were more dependent on surgeons’ decisions 
before. 
 
Conclusion: some perspectives of comparison 
 
It cannot be denied that institutional conditions favoured the emergence and the relative easy 
acceptance of this reform by other CCs’ actors. First, as we wrote above, the emphasis on the 
development of clinical research in Cancer Centres as well as the commitment to producing 
guidelines corresponds to a major trend in modern medicine (Marks 1997; Timmermans and 
Berg 2003; Daly, 2005). Secondly, it corresponds to the rise of medical oncology as a 
speciality strongly linked with clinical research (Löwy, 1996; Cambrosio, 2005). For instance, 
in the middle of the 1980s, medical oncologists became the dominant speciality at the 
NFCC’s board (see Annex 2) – even if their colleagues had a far smaller experience in 
(international) clinical research than the reformers. Thirdly, it was in line with growing 
considerations for quality by regulation bodies, which facilitated their (financial and political) 
support. 
International comparisons should allow us to weigh the impact of these broad factors on the 
social phenomena that we described. To what extent can we observe convergent changes on 
an international scale? Comparisons should address the following dimensions: 
1) categories of actors and organisations who (possibly) gave the initial impulse to 
changes in the organisation of cancer care; 
2) initial content of the projects for change and reasons why they are thus designed; 
3) processes of implementation; 
4) evolution in cancer care. 
One may first hypothesise that the relative development of cancer treatment modalities in 
different countries (Pickstone, 2007) impacts the change process. In the same vein, can the 
relative development of cancer hospitals in different countries and their characteristics be 
related to organisational changes? Indeed, we saw that some of the historical characteristics of 
cancer centres seemed to facilitate the emergence and the diffusion of the reform inside CCs. 
To what extent is this true? Other differences may depend on the organisation and funding of 
the respective healthcare systems. In France, on the one hand, the competition between 
Teaching Hospitals and Cancer Centres and, on the other hand, the informal hierarchical 
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relationships between hospitals may explain the dynamics of the reform. For instance, French 
oncology networks should not be confused with American HMO or English trusts. These 
peculiarities may impact change processes in the different countries. 
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ANNEX 1 
 
Evolution of the budget of the Federation 
 
 
 
- 
1 
2 
3 
4 
5 
6 
7 
8 
1991 1992 1993 1994 1995 1996 1997 1998 1999 2000
Budget (M€) Wage costs (M€)
 
8 
Sites and Styles: Exploring the Comparative History of Cancer CHSTM, Manchester, March 2007 
ANNEX 2 
 
 
Medical specialities of the CCs' directors (1950-2000)
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